Quadrivalent recombinant influenza vaccine

Quadrivalent recombinant influenza vaccine (RIV4) is a type of seasonal flu vaccine designed to protect against four different strains of the influenza virus—two influenza A viruses and two influenza B viruses. Unlike traditional egg-based or cell-cultured vaccines, RIV4 is produced using recombinant DNA technology, which does not require the use of chicken eggs in manufacturing. This approach allows for rapid production and avoids issues related to egg allergies. The primary mechanism involves introducing purified hemagglutinin proteins from the targeted viral strains into the body, stimulating an immune response that provides protection against future infection by those strains. Quadrivalent recombinant vaccines are indicated for active immunization to prevent disease caused by these specific subtypes and lineages of influenza virus[1][2][3][4]. Major brands include Flublok (marketed in the US) and Supemtek (marketed in Europe). The main indication is prevention of seasonal influenza.

Brand names

FlublokSupemtek

Other names

RIV4 quadrivalent recombinant flu vaccineRIV-4 quadrivalent recombinant flu vaccineRIV 4 quadrivalent recombinant flu vaccine